Abstracts

376 – Candida-Responsive Cells Contain Intact HIV-1 DNA Despite Limited Clonality in Blood

Background The persistence of a stable reservoir of HIV-1 infected CD4⁺ T cells during antiretroviral therapy (ART) remains the central barrier to a cure. Antigen-driven proliferation of infected cells is a major driver of reservoir persistence, yet the role of repeated antigen stimulation from commensal microbes is poorly defined. Candida albicans (CA), a ubiquitous commensal…

664 – Associations of Inflammatory Biomarkers With CVD Burden and Predicted Risk in People With HIV

Background People with HIV have increased cardiovascular disease (CVD) risk, partly driven by persistent inflammation. We assessed associations of inflammatory biomarkers with current CVD burden and 10-year risk in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study. Methods In POPPY participants with HIV, a CVD pattern was identified using principal component analysis…

960 – Pilot Validation of an Enzymatic Assay With Lateral Flow Readout for Long-Term PrEP Adherence

Background Point-of-care medication adherence tests can be used in clinical trials and routine care to monitor and improve HIV health outcomes. Urine tenofovir lateral flow assays (LFAs) are rapid and inexpensive but cannot distinguish between recent (<1 week) and long-term (1-3 month) adherence. The REverse transcriptase ACTivity (REACT) assay measures tenofovir diphosphate (TFV-DP), a metabolite…

969 – Cost-Effectiveness of HIV Monitoring for Long-Acting Cabotegravir Preexposure Prophylaxis in the US

Background While the US Centers for Disease Control and Prevention recommends dual HIV testing with antigen/antibody (Ag/Ab) and RNA tests during long-acting injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP), the optimal strategy for monitoring people on CAB-LA for HIV is uncertain. Methods Using a microsimulation model, we compare three monitoring strategies for US men who…

986 – Diagnostic Outcomes After Detectable HIV-1 RNA in Persons on CAB-LA PrEP in Routine Care in US

Background CAB PrEP is highly effective but rare instances of HIV acquisition have occurred in trials and clinical care. HIV diagnosis among persons on CAB PrEP can be complicated by viremia suppression, delayed seroconversion, and false-positive HIV RNA results. We examined HIV detection, provider-selected ART or PrEP, and diagnostic outcomes in individuals with unconfirmed detectable…

521 – Nonclinical Pharmacology of GS-3242, a Novel Long-Acting Injectable InSTI in Clinical Development

Background The development of integrase strand transfer inhibitors (INSTIs) compatible with long-acting injectable (LAI) lenacapavir (LEN) dosing would provide significant unmet need to people with HIV-1 (PWH) who struggle to take pills. Herein we describe the nonclinical virology and safety profile of GS-3242, an investigational INSTI with PK supportive of at least once every 3…

541 – Viro-Immunologic Success Against the Odds: 7-Year Outcome in People With 4-Class Drug-Resistant HIV 

Background Heavily treatment-experienced (HTE) people with HIV (PWH) are at increased risk of suboptimal virological suppression and immune recovery. Our aim was to assess these outcomes longitudinally in individuals with 4-class drug resistance (4DR). Methods Repeated cross-sectional analyses were conducted in the PRESTIGIO Registry, an ongoing multicenter cohort that prospectively collects data and provides multidisciplinary evaluation…

987 – Characterization of HIV Acquisitions on Long-Acting Cabotegravir PrEP From ImPrEP CAB Brasil

Background HIV acquisition during long-acting cabotegravir (CAB) PrEP is rare but poses significant challenges for HIV detection and monitoring within prevention programs. We present the first analysis of HIV-1 acquisitions on CAB PrEP in routine public health settings in Brazil. Methods ImPrEP CAB Brasil is an implementation study of same‐day CAB initiation at oral PrEP…

549 – Housing Status and HIV Viral Suppression Across 4 United States Cohorts

Background People with HIV (PWH) in the US experience homelessness at greater proportions than the general population. There remains a lack of understanding regarding HIV clinical care outcomes, including achievement of viral suppression, among PWH experiencing homelessness in different settings. Methods We evaluated associations between housing status and HIV viral suppression using harmonized data from four…

650 – Predictors of Cardiovascular Events Among Ugandan Adults on Long-Term ART: A Prospective Study

Background  People living with HIV (PLWH) face a two-fold increased lifetime risk of cardiovascular (CDV) diseases compared to those without. This trend that has become more evident as ART has extended life expectancy. Nearly two-thirds of PLWH live in Sub-Saharan Africa, where evidence on long-term CDV outcomes remains limited. We conducted a prospective study within…